Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma, Non-Hodgkin

In brief

The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).

Key facts

Study ID

NCT00347971

Run by

ZymoGenetics

People needed

23

Starts

2006-06-01

Expected to finish

2008-04-01

Last updated by the study team

2008-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of CD20+ B-cell NHL
• Disease measurable by computed tomography (CT) scan
• Has failed at least one prior systemic therapy for NHL
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate hepatic and renal function
• Adequate bone marrow function

You may not qualify if…

• Presence of acute infection or other significant systemic illness
• White blood cell (WBC) count > 50,000/mm3 in peripheral blood
• Central nervous system involvement by malignancy
• Previous allogenic transplant or autotransplant within 6 months of enrollment
• Other current malignancy or known history of cancer within 5 years
• Received systemic corticosteroids, chemotherapy, immunotherapy, biologic therapy, antibody therapy (e.g., rituximab), radiation therapy, and/or investigational agent(s) within 1 month of enrollment

Where it is running

• University of California, Los Angeles — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.